In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli

New Microbiol. 2009 Jan;32(1):49-55.

Abstract

We investigated in vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against Gram-negative bacilli. Piperacillin/tazobactam 8:1 lowered resistance for Escherichia coli, Serratia marcescens, Enterobactaer cloacae, Klebsiella pneumoniae and imipenem-susceptible Acinetobacter baumannii. When piperacillin was combined with sulbactam 2:1 or 4:1, resistance against E. coli, S. marcescens, E. cloacae, extended spectrum beta-lactamase (ESBL)-K. pneumoniae and A. baumannii were reduced. MIC90 of cefoperazone against S. marcescens, E. cloacae, ESBL-K. pneumoniae and A. baumannii were >128 mg/L. Addition of sulbactam 1:1 or 2:1 enhanced antimicrobial activities. Addition of sulbactam to piperacillin or cefoperazone enhanced antimicrobial activities of GNB.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Cefoperazone / pharmacology*
  • Drug Therapy, Combination
  • Enzyme Inhibitors / pharmacology
  • Gram-Negative Bacteria / classification
  • Gram-Negative Bacteria / drug effects*
  • Humans
  • Microbial Sensitivity Tests
  • Penicillanic Acid / analogs & derivatives
  • Penicillanic Acid / pharmacology
  • Piperacillin / pharmacology*
  • Sulbactam / pharmacology
  • Tazobactam
  • beta-Lactamase Inhibitors*
  • beta-Lactams / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Enzyme Inhibitors
  • beta-Lactamase Inhibitors
  • beta-Lactams
  • Cefoperazone
  • Penicillanic Acid
  • Sulbactam
  • Tazobactam
  • Piperacillin